Datos del evento
RNA-guided genome editing by engineered CRISPR-Cas systems has revolutionized biological research and promises to do likewise for biomedical applications. Genome editing is now firmly entrenched as a tool for biomedical research, but the road towards clinical applications – i.e., realizing the longstanding dream of true cures for inherited diseases – will take longer, given the delivery challenges that must be met and the safety and efficacy thresholds that must be achieved. The molecular and structural characterization of known and novel CRISPR-Cas systems and the capabilities of genome editing platforms continue to expand, our ability to measure editing outcomes is increasing, and biomedical applications are just getting under way. We are therefore entering a crucial phase in the field’s evolution, and researchers in the CRISPR-Cas field, from basic microbiology to clinical applications, will continue to be eager to share their advances with colleagues and participate in the discussions and debates that will be needed to spur progress.